The Regulatory Boundary Between Research and Clinical Investigation

Not every compound under scientific study requires formal regulatory oversight. A peptide synthesised in a laboratory and studied in cell culture or animal models occupies a distinct regulatory space from one intended for administration to human subjects. The point at which that distinction becomes legally significant is defined by 21 CFR Part 312, the federal regulation governing Investigational New Drug applications in the United States [1].

Under this framework, a compound is classified as investigational when a sponsor intends to conduct clinical investigations — defined as studies in human subjects — with a drug that has not received marketing approval for the proposed use. The classification is not determined by the compound's novelty, its mechanism of action, or its perceived therapeutic potential. It is determined by intent: the moment a sponsor plans to administer a substance to a human being for research purposes, the IND requirement is triggered [1].

This distinction carries practical weight for researchers working with peptide compounds. Preclinical work — including in vitro assays, pharmacokinetic modelling in animal models, and exploratory toxicology — may proceed without IND submission. The regulatory threshold is crossed only when the research programme advances toward human subjects.

Defining 'Investigational' Status Under 21 CFR Part 312

The regulation at 21 CFR 312.3 defines an investigational new drug as a pharmaceutical compound for which an IND is in effect. More precisely, it is a new drug or biological drug used in a clinical investigation [1]. For peptide compounds — which may straddle the definitional boundary between small molecules and biologics depending on their size and origin — this classification has particular relevance.

Peptides synthesised chemically and comprising fewer than approximately 40 amino acids are generally regulated as drugs under the Federal Food, Drug, and Cosmetic Act, rather than as biologics under the Public Health Service Act. Larger peptides and those derived from biological sources may fall under biologic regulation. The regulatory pathway selected has downstream consequences for the IND data package required, the manufacturing standards applied, and the ultimate approval route available [2].

For compounds that remain in preclinical settings — studied exclusively in non-human systems — no IND is required. These compounds are sometimes described informally as research compounds, a classification that reflects their stage of development rather than any formal regulatory designation. The absence of an IND does not imply regulatory indifference; it simply means the compound has not yet reached the threshold that mandates formal FDA engagement.

Triggers for IND Submission

Intent to Test in Humans

The primary trigger for IND submission is the intent to administer a compound to human subjects in a clinical investigation [1]. This includes Phase 1 safety studies, exploratory pharmacokinetic studies in healthy volunteers, and early proof-of-concept studies in patient populations. The intent trigger is prospective: the IND must be submitted and the 30-day review period must elapse before the first human dose is administered.

Toxicology Benchmarks and Safety Data Readiness

Before an IND can be submitted responsibly, a minimum toxicology dataset is expected. FDA guidance on preclinical safety evaluation specifies that the nature and extent of toxicology studies should be commensurate with the proposed clinical programme [2]. For a first-in-human study involving a novel peptide, this typically includes single-dose and repeat-dose toxicology studies conducted under Good Laboratory Practice conditions, genotoxicity assessments, and safety pharmacology evaluations covering cardiovascular, respiratory, and central nervous system endpoints.

The species selection for these studies is not arbitrary. For peptides, pharmacological activity may be species-specific, and the relevance of a given animal model to human biology must be justified scientifically [2]. When no pharmacologically relevant animal species exists, alternative approaches — including in vitro studies or studies in transgenic animals — may be discussed with FDA prior to IND submission through the pre-IND meeting process.

Manufacturing Scale and CMC Readiness

Chemistry, Manufacturing, and Controls information constitutes a distinct and substantial component of the IND application. For peptide compounds, CMC requirements reflect the complexity of peptide synthesis, purification, and characterisation [3]. At the IND stage, the CMC package need not demonstrate commercial-scale manufacturing capability; it must, however, demonstrate that the material to be used in clinical studies is adequately characterised, consistently manufactured, and sufficiently stable for the proposed study duration.

For synthetic peptides, this includes a description of the synthetic route, specification of starting materials and reagents, analytical methods for identity and purity testing, and data on impurity profiles [3]. The presence of process-related impurities — including truncated sequences, oxidised variants, and residual protecting groups — must be identified and, where relevant, qualified through toxicology studies.

Components of the IND Application

An IND application is assembled from several distinct data packages, each reviewed by a different discipline within FDA's review division.

Pharmacology and Toxicology Section

This section presents the preclinical evidence that the compound can be administered to humans at the proposed doses without unreasonable risk. It includes summaries of all pharmacology studies demonstrating the compound's mechanism of action and biological activity, followed by the toxicology dataset described above [1]. For peptide compounds, this section must also address the potential for immunogenicity — the capacity of the peptide to elicit an immune response in humans — which is discussed in greater detail below.

Clinical Protocol and Investigator Information

The proposed Phase 1 clinical protocol must be included in the IND submission. This document specifies the study design, subject selection criteria, dose escalation scheme, safety monitoring procedures, and stopping rules [1]. The protocol is reviewed for whether it exposes subjects to unnecessary risk and whether the monitoring provisions are adequate to detect emerging safety signals.

Investigator qualifications — including curriculum vitae and documentation of training in Good Clinical Practice — are submitted alongside the protocol. The principal investigator bears regulatory responsibility for the conduct of the study at their site.

Manufacturing Information

The CMC section, as described above, provides FDA with confidence that the investigational compound is what the sponsor claims it to be and that it will be manufactured consistently across the clinical supply chain [3]. At the IND stage, this is an evolving document; sponsors are expected to update CMC information as manufacturing processes are refined and as additional characterisation data become available.

The 30-Day Review Clock and IND-Allowed Status

Upon receipt of an IND submission, FDA has 30 calendar days to review the application and, if warranted, place it on clinical hold [1]. If no clinical hold is imposed within that period, the IND is considered to be in effect and the sponsor may proceed with the clinical investigation. This status is sometimes described as IND-allowed, reflecting the absence of FDA objection rather than affirmative approval of the compound or the study.

The distinction is significant. An IND in effect does not constitute a finding that the compound is safe or effective. It reflects FDA's determination, based on available data, that the proposed study does not present an unreasonable risk to human subjects and that the protocol is adequate to protect their welfare. The regulatory process is a threshold determination, not an endorsement.

Clinical Holds: When Preclinical Data Triggers Regulatory Intervention

FDA retains authority to impose a clinical hold — an order to delay or suspend clinical investigation — at any point during the IND process [1]. Clinical holds are imposed when the agency determines that human subjects would be exposed to unreasonable and significant risk, that the investigator is not qualified, that the investigational plan is inadequate to evaluate safety, or that the IND application contains materially false information.

For peptide compounds, common preclinical signals that may prompt a clinical hold include unexpected toxicity findings in repeat-dose animal studies, evidence of off-target pharmacological activity at clinically relevant exposures, inadequate characterisation of immunogenic potential, or manufacturing data suggesting unacceptable impurity levels. When a clinical hold is imposed, the sponsor must address the agency's concerns in a complete response before clinical activities may resume.

Peptide-Specific Regulatory Considerations

Immunogenicity Assessment

Immunogenicity — the potential for a therapeutic peptide to elicit anti-drug antibodies or other immune responses — is a regulatory concern that distinguishes peptide INDs from those for conventional small molecules [2]. FDA guidance on immunogenicity assessment for therapeutic protein and peptide products specifies that sponsors should evaluate immunogenic potential as part of the preclinical programme and include a plan for monitoring anti-drug antibodies in the clinical protocol [2].

The consequences of immunogenicity in clinical settings range from pharmacokinetic variability to serious adverse events, including anaphylaxis and cross-reactivity with endogenous proteins. For peptides that share sequence homology with endogenous human proteins, the immunogenicity risk profile requires particular attention.

Manufacturing Complexity and GLP Expectations

Peptide synthesis introduces manufacturing complexity not present in small-molecule chemistry. Solid-phase synthesis, solution-phase synthesis, and hybrid approaches each carry distinct impurity profiles and scalability considerations. FDA expects that toxicology studies submitted in support of an IND are conducted with material that is representative of the clinical supply — meaning that the synthesis route, purification process, and analytical specifications used for GLP toxicology batches should closely mirror those intended for clinical manufacture [3].

Where significant changes to the manufacturing process occur between the toxicology batches and the clinical supply, bridging studies may be required to demonstrate comparability.

Post-IND Transition: Phase 1 Data and Regulatory Strategy

Phase 1 safety data collected under an active IND inform subsequent regulatory strategy in several important ways. For peptide compounds seeking eventual marketing approval, the choice between a full 505(b)(1) new drug application — requiring a complete independent data package — and a 505(b)(2) application — which may rely in part on published literature or data from previously approved compounds — is shaped by the compound's relationship to existing approved peptides.

A peptide that is structurally novel with no approved reference compound will typically require the 505(b)(1) pathway. A peptide that is a modified form of an approved compound, or one for which substantial published safety and pharmacology data exist, may be eligible for the 505(b)(2) route, potentially reducing the data burden required for approval. Phase 1 findings on safety, tolerability, and pharmacokinetics in humans provide the empirical foundation for these strategic decisions.

International Considerations: The IMPD and EMA Framework

Sponsors conducting clinical investigations in the European Union operate under a parallel framework governed by the Clinical Trials Regulation (EU No 536/2014) and its predecessor, Directive 2001/20/EC. The European equivalent of the IND application is the Investigational Medicinal Product Dossier, or IMPD, which is submitted as part of a clinical trial authorisation application to the relevant national competent authority and ethics committee.

The IMPD shares structural similarities with the FDA IND — it includes quality (CMC), non-clinical, and clinical sections — but differs in several procedural and substantive respects. The EMA's guidelines on non-clinical safety studies for the conduct of human clinical trials, published under the ICH S6 and ICH M3 frameworks, govern the toxicology data expectations for peptide IMPDs. Immunogenicity assessment requirements are addressed under EMA's guideline on immunogenicity assessment of therapeutic proteins.

For sponsors pursuing simultaneous clinical development in the United States and European Union, alignment of the preclinical data package to satisfy both FDA and EMA expectations from the outset — rather than conducting separate studies for each jurisdiction — represents a significant efficiency. Pre-submission meetings with both agencies, available prior to IND and IMPD submission respectively, provide an opportunity to confirm data package adequacy before studies are completed.

The IND as a Regulatory Threshold, Not a Safety Determination

The IND process is frequently misunderstood as a form of regulatory approval. It is not. An IND in effect means that a sponsor has assembled sufficient preclinical data to justify the risk of initial human exposure under controlled conditions, and that FDA has not identified grounds to prevent that exposure within the 30-day review window.

The compound remains investigational throughout the clinical development process. Its safety and efficacy for any specific use are not established until the full clinical programme is completed and a marketing application is reviewed and approved. For peptide compounds in particular — where preclinical models may imperfectly predict human pharmacology and immunogenicity — the IND represents the beginning of a rigorous evidentiary process, not its conclusion.

Understanding this threshold with precision matters for researchers, sponsors, and anyone engaged with the regulatory landscape of peptide science. The IND application is the formal instrument through which the scientific community and the regulatory system enter into a structured dialogue about human risk — a dialogue governed by data, defined by statute, and conducted under the continuous oversight of FDA's review authority.